Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
Aptinyx Inc. (Nasdaq: APTX) announced its participation in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13 at 3:40 p.m. ET. A live webcast will be available to Cowen clients. Aptinyx focuses on developing therapies for nervous system disorders, emphasizing a unique mechanism to modulate NMDA receptors. The company has three product candidates targeting chronic pain, PTSD, and cognitive impairment, along with a robust pipeline of small-molecule NMDA receptor modulators aimed at various neurological conditions.
- None.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005222/en/
FAQ
What is Aptinyx's stock symbol?
When will Aptinyx participate in the Cowen Summit?
What is the focus of Aptinyx's drug development?
What kind of therapies is Aptinyx developing?
What conditions are targeted by Aptinyx's product candidates?
